Isoleucine
Key facts at a glance
- ATC
- unclassified
- RxNorm
- 6038
- Generic
- Isoleucine
- Class
- unclassified
- Brands
- Freamine III 10, Clinimix E 4.25/10, Aminosyn II 8.5 % with Electrolytes, Sulfite-Free, Aminosyn 8.5 % with Electrolytes, Sulfite-Free, Trophamine 10 %, Trophamine 6 %, Plenamine, Prosol, PremaSol, Aminosyn II 15%, Aminosyn II 8.5 %, Sulfite-Free, Aminosyn II 10 %, Aminosyn-HBC 7 %, Sulfite-Free, Aminosyn-PF 10 %, Sulfite-Free, Clinimix E 4.25/5
- Availability
- otc
- Pregnancy
- C
- Lactation
- caution
- Half-life (h)
- 2
- Onset (min)
- 0
- Duration (h)
- 0
- Routes
- oral, intravenous
- Forms
- capsule, powder, injectable solution
- Regions
- United States, Canada, European Union, Australia, Japan
- Monitoring
- serum amino acid levels, liver function tests, renal function, electrolytes
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy